Altered NCAM expression associated with the cholinergic system in Alzheimer's disease
- PMID: 20164549
- DOI: 10.3233/JAD-2010-1398
Altered NCAM expression associated with the cholinergic system in Alzheimer's disease
Abstract
Neurotransmitter system dysfunction and synapse loss have been recognized as hallmarks of Alzheimer's disease (AD). Our hypothesis is that specific neurochemical populations of neurons might be more vulnerable to degeneration in AD due to particular deficits in synaptic plasticity. We have studied, in postmortem brain tissue, the relationship between levels of synaptic markers (NCAM and BDNF), neurochemical measurements (cholinacetyltransferase activity, serotonin, dopamine, GABA, and glutamate levels), and clinical data (cognitive status measured as MMSE score). NCAM levels in frontal and temporal cortex from AD patients were significantly lower than control patients. Interestingly, these reductions in NCAM levels were associated to an ApoE4 genotype. Levels of BDNF were also significantly reduced in both frontal and temporal regions in AD patients. The ratio between plasticity markers and neurochemical measurements was used to study which of the neurochemical populations was particularly associated to plasticity changes. In both the frontal and temporal cortex, there was a significant reduction in the ChAT/NCAM ratio in AD samples compared to controls. None of the ratios to BDNF were different between control and AD samples. Furthermore, Pearson's product moment showed a significant positive correlation between MMSE score and the ChAT/NCAM ratio in frontal cortex (n=19; r=0.526*; p=0.037) as well as in temporal cortex (n=19; r=0.601*; p=0.018) in AD patients. Altogether, these data suggest a potential involvement of NCAM expressing neurons in the cognitive deficits in AD.
Similar articles
-
Decreased levels of BDNF protein in Alzheimer temporal cortex are independent of BDNF polymorphisms.Exp Neurol. 2005 Jul;194(1):91-6. doi: 10.1016/j.expneurol.2005.01.026. Exp Neurol. 2005. PMID: 15899246
-
Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease.Neuropsychologia. 2005;43(3):442-9. doi: 10.1016/j.neuropsychologia.2004.06.007. Neuropsychologia. 2005. PMID: 15707619
-
Neurotransmitter changes in Alzheimer's disease: implications to diagnostics and therapy.J Neurosci Res. 1990 Dec;27(4):576-86. doi: 10.1002/jnr.490270419. J Neurosci Res. 1990. PMID: 1981917
-
[Neuropathology of Alzheimer's disease and mild cognitive impairment].Rev Neurol. 2003 Jul 16-31;37(2):155-63. Rev Neurol. 2003. PMID: 12938076 Review. Spanish.
-
Beyond the Hypothesis of Serum Anticholinergic Activity in Alzheimer's Disease: Acetylcholine Neuronal Activity Modulates Brain-Derived Neurotrophic Factor Production and Inflammation in the Brain.Neurodegener Dis. 2015;15(3):182-7. doi: 10.1159/000381531. Epub 2015 Jun 30. Neurodegener Dis. 2015. PMID: 26138497 Review.
Cited by
-
Cell adhesion molecules in Alzheimer's disease.Degener Neurol Neuromuscul Dis. 2012 Jul 4;2:65-77. doi: 10.2147/DNND.S19829. eCollection 2012. Degener Neurol Neuromuscul Dis. 2012. PMID: 30890880 Free PMC article. Review.
-
Meta-analysis of synaptic pathology in Alzheimer's disease reveals selective molecular vesicular machinery vulnerability.Alzheimers Dement. 2016 Jun;12(6):633-44. doi: 10.1016/j.jalz.2015.12.005. Epub 2016 Jan 14. Alzheimers Dement. 2016. PMID: 26776762 Free PMC article.
-
Genome-wide pathway analysis of memory impairment in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks.Brain Imaging Behav. 2012 Dec;6(4):634-48. doi: 10.1007/s11682-012-9196-x. Brain Imaging Behav. 2012. PMID: 22865056 Free PMC article.
-
Neuronal MHC-I complex is destabilized by amyloid-β and its implications in Alzheimer's disease.Cell Biosci. 2023 Sep 29;13(1):181. doi: 10.1186/s13578-023-01132-1. Cell Biosci. 2023. PMID: 37773139 Free PMC article.
-
Amyloid precursor protein (APP) and amyloid β (Aβ) interact with cell adhesion molecules: Implications in Alzheimer's disease and normal physiology.Front Cell Dev Biol. 2022 Jul 26;10:969547. doi: 10.3389/fcell.2022.969547. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35959488 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous